All In Biotech

Drug Trial Radar · NCT03813199

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα

Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Jul 4, 2019

Primary completion

Apr 27, 2021

Study completion Apr 27, 2021

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
Jan 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one or more anti- tumor necrosis factor alpha (TNFα) therapies.

Conditions

  • Rheumatoid Arthritis

Interventions

  • ABX464 50mgDrug

    ABX464 is a new anti-inflammatory drug

  • Matching PlaceboDrug

    placebo matching with ABX464

  • ABX464 100mgDrug

    ABX464 is a new anti-inflammatory drug

  • MethotrexateDrug

    MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus PlaceboTime frame: through study completion, an average of 15 weeks

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • ZNA Jan Palfijn

    Merksem, Belgium

  • Fakultni Tomayerova nemocnice

    Prague, Czechia

  • Revmatologicky ustav

    Prague, Czechia

  • CHU de Brest - Hôpital Cavale Blanche

    Brest, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHU de Montpellier - Lapeyronie

    Montpellier, France

  • GHR Mulhouse Sud-Alsace

    Mulhouse, France

  • CHU de Nice - Hôpital Pasteur

    Nice, France

  • CHR d'Orléans

    Orléans, France

  • APHP - Hôpital Salpétrière

    Paris, France

  • CHU de Tours - Hôpital Trousseau

    Tours, France

  • Complex Medical Centre - Déli Klinika

    Budapest, Hungary

  • CRU Hungary Ltd.

    Miskolc, Hungary

  • CMed Rehabilitációs és Diagnosztikai Központ

    Székesfehérvár, Hungary

  • ClinicMed Daniluk, Nowak Sp. J.

    Bialystok, Poland

  • Pratia MCM

    Krakow, Poland

  • Zespół Poradni Specjalistycznych REUMED

    Lublin, Poland

  • NZOZ Lecznica MAK-MED S.C.

    Nadarzyn, Poland

  • Medyczne Centrum Hetmańska

    Poznan, Poland

  • National Institute of Geriatrics

    Warsaw, Poland

  • RHEUMA MEDICUS Zakład Opieki Zdrowotnej

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.